Close Menu

NEW YORK – Illumina said on Friday that it has received medical device registration in Russia for its NextSeq 550Dx sequencing platform, associated reagent kits, and reagents for the MiSeq Dx sequencer, which was previously approved in Russia.

R-Pharm, Illumina's strategic partner in Russia and the Commonwealth of Independent States (CIS), led the regulatory process, which requires separate approvals of sequencing platforms and reagents by the Russian medical device regulatory agency, Roszdravnadzor.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.